2 years later it's still remission! "K medicine" is expected to be the first line of treatment for metastatic colorectal cancer

▌ colorectal cancer, more than 80% of the found is that middle and late colorectal cancer is China and the world's third largest cancer, but also the second most common cause of cancer-related deaths, good in people over 45 years of age.
cancer in the colorectal area usually needs to go through the development process of →intestinal →intestinal cancer", the pathogenesis is relatively clear.
because the early symptoms are not obvious, the majority of colorectal cancer patients in China are in the middle and late stages of diagnosis.
but in fact, as long as attention to screening, timely detection and removal of pyma, can block cancer, just regular review. Dr. Michael Castro, an oncologist at
Good Medical Friends Medical Network, who has been named "America's Top Doctor" several times, points out that early detection of colorectal cancer, through surgery and complementary chemotherapy, results in a five-year survival rate of more than 90%;
today, treatments for advanced colorectal cancer have also improved considerably.
Castro, the main treatments for colorectal cancer include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
MSI and MMR are like "fixers" stationed in the body, specializing in DNA bug fixing.
these genes mutate, errors in DNA replication cannot be repaired in time, and cancer cells are more likely to cause cancerous mutations.
about 5% of patients with metastatic colorectal cancer carry MSI-H or dMMR, and the standard treatment for such patients is chemotherapy, but is often insensitive to conventional chemotherapy.
, however, MSI-H and dMMR tumors carry a large number of genetic mutations in their genomes due to abnormal DNA repair mechanisms in cells, making them more sensitive to immunosuppressants.
▌ "K-drug": has been approved to treat more than 20 kinds of cancer Pabliju monoantimmune mainly by strengthening the body's immune system to help identify and fight tumor cells.
it blocks the binding of PD-1 receptors on the surface of T cells to their receptors, activating T-cells to attack tumors.
"star immunotherapy" Pabli juju single resistance has been in the public eye since it was approved for sale in 2014.
this cancer immunotherapy has shown a welcome efficacy in a number of cancers and can be used to treat melanoma, head and neck cancer, non-small cell lung cancer, classic Hodgkin's lymphoma, bladder cancer, stomach cancer, etc.
, Pabliju monoantigen has been shown to work in more than 20 cancers, as well as benefits for patients with MSI-H or dMMR metastatic colorectal cancer.
▌ clinical data amazing, 2 years later still continue to ease! A key Phase 3 clinical trial (KEYNOTE-177) compared the effectiveness and safety of Pabli pearl monoantigen and chemotherapy in 307 patients with MSI-H or dMMR metastatic colorectal cancer.
data have been published in the New England Journal of Medicine.
results showed that after 32.4 months of medium follow-up, the Paboliju monoantitherapy group was better than the chemotherapy group (16.5 VS 8.2 months) in terms of non-progression survival.
, the overall remission rates of the Pabliju monoantigen and chemotherapy groups were 43.8% and 33.1%, respectively.
in patients who achieved overall remission, 83% of patients in the Pabliju monoantigen group continued to remission after 2 years.
currently, the main course of treatment for most MSI-H/dMMR colorectal cancer patients is chemotherapy, but the effect is limited.
the ability to significantly prolong the progress-free survival of such patients, which is expected to benefit more bowel cancer patients.
, colorectal cancer is not a single disease and is highly heterogeneous.
clinical experience has shown that a "one size fits all" approach to colorectal cancer should not be used, but that multidisciplinary specialists are needed to develop personalized and precise treatment options based on the specific mutations and interactions of patients.
: The main screening methods for colorectal cancer include: colonoscopy, fecal latent blood test, virtual colonoscopy (CT colonoscopy), DNA testing, double contrast enema (less commonly used).
is the gold standard for colorectal cancer screening, early screening, early detection, early treatment is the most effective way to fight bowel cancer.
Castro suggests that healthy people should start screening at age 45.
if you have a family history of colorectal cancer, you should start regular check-ups at age 40, or start 10 years before the age at which a member of the family is diagnosed, whichever is earlier.
。